Meds, Mind, Body & Benefits > Research News & Studies
CAPRISA - PrEP Phase 1 TAF implant
(1/1)
Jim Allen:
The implant drug release rates did not reach targeted concentrations in most participants and there were tolerability issues.
In Full: Polly Clayden, HIV i-Base https://i-base.info/htb/47854
In Brief:
--- Quote ---The CAPRISA 018 phase 1 trial looked at an annual TAF implant in low-risk adult South African cisgender women without HIV.
The silicone implant, developed by the Oakcrest Institute, has the same dimensions as a contraceptive implant (40 mm length and 2.5 mm OD), except with two delivery channels. It is loaded with 110 mg TAF free-base micro-tablets. Target release 0.25 mg/day.
Overall, 31% (11/36) were removed early (before 48 weeks) at a median of 19 weeks (range: 2 to 27); of these 55% were participant-initiated and the remainder clinician-initiated. These were mostly associated with ISRs. --- End quote ---